J

Jazz Pharmaceuticals

Biopharmaceuticals focused on neuroscience and oncology

KOL & External Engagement Platforms Technical Lead

Full-Time
$141.6k - $212.4k
Senior
Bachelor's
Pennsylvania, USA
RemoteRequires 10–20% travel.
Software Engineering

About the job

Requirements
  • Experience designing, testing, deploying, operating, and enhancing scalable, secure, and compliant technology solutions for large-scale organizational use.
  • Understanding of enterprise software architecture, cloud platforms, modern engineering frameworks, system integration patterns, application programming interfaces, and data architecture across enterprise technology platforms.
  • Knowledge of KOL identification and engagement strategies, event execution workflows, HCP compliance and consent requirements, speaker program management and governance, and performance tracking frameworks.
  • Ability to translate engagement strategies into durable, reusable data and platform capabilities.
  • Experience managing vendor-heavy ecosystems, including roadmap alignment, integration standards, and delivery accountability.
  • Ability to integrate engagement platforms with CRM, analytics, and data platforms for measurement and optimization.
  • Strong understanding of event and engagement management platforms, KOL identification and engagement tools, and vendor-supported engagement solutions.
  • Experience designing and integrating enterprise digital platforms such as Veeva Events Portal, SpotMe, Cadence, HCP EngageNow, IFI/MB4, and Patient Advocacy/Conference Engagement Tools.
  • Ability to partner with Global Capability Owners to translate executive and franchise requirements into scalable, well-governed technology solutions with roadmaps and prioritization.
  • Ability to provide technical leadership on standardization, KPI implementation, and architectural tradeoffs to ensure enterprise technology assets remain consistent, performant, and extensible across brands and regions.
  • Experience leading mixed teams of internal developers and vendors, including technical direction, code and dashboard reviews, estimation, and delivery accountability.
  • Ability to collaborate with UX researchers and UI designers, with a user-centric mindset applied to technical development.
  • Experience working within Agile product development teams and product operating models.
  • Ability to understand the customer's end-to-end journey and use it for ongoing go-to-market strategic, tactical, and measurement decisions while anticipating needs across touchpoints.
  • Ability to identify opportunities to improve customer experience and company performance through digital tools, data, and automation.
  • Ability to work across teams and reporting lines, coordinate shared work, and ensure progress when accountability is distributed.
  • Ability to assess inputs objectively, challenge assumptions, and make sound, forward-looking judgments.
  • Ability to adopt new tools, ways of working, and behaviors.
  • Bachelor's degree in computer science, engineering, information systems, or a related technical field.
  • At least 7 years of experience after a bachelor's degree, or at least 5 years after a master's degree, in customer engagement, KOL management, event and congress operations, patient advocacy, or related pharmaceutical domains.
  • At least 2 years of experience as a Tech Lead, Technical Program Manager, Engineering Manager, or in another role involving management of a team of developers.
  • Expertise in engagement platforms, speaker programs, and compliant customer experience delivery across HCPs, patients, and caregivers.
  • Demonstrated experience designing and delivering enterprise-scale digital platforms, such as engagement platforms, event management systems, CRM-integrated solutions, or external interaction management systems.
  • Experience working within complex, matrixed organizations with multiple technology and product teams.
  • Proven ability to mentor and guide developers and vendor partners to deliver high-quality solutions.
Responsibilities
  • Partner with the KOL & External Engagement Platforms Global Capability Owner to design solutions to business problems and provide technical insight on capabilities, effort levels, and tradeoffs.
  • Collaborate with the Customer Operations Technical Suite Lead and architects to translate capability roadmaps into scalable technology architectures and development plans, assessing feasibility, constraints, dependencies, and risks.
  • Convert complex business requirements into clear technical specifications and executable technical work tasks.
  • Execute technical activities and drive work plans for building, configuring, and integrating software aligned to business needs and technology standards, including HCP EngageNow, Veeva Events Portal, SpotMe, Cadence, and similar engagement and event platforms.
  • Work with integration frameworks to connect engagement platforms with CRM, analytics, and compliance systems.
  • Translate technical requirements into well-defined development work, lead Agile ceremonies, ensure disciplined roadmap execution, and take ownership of complex technical challenges end to end.
  • Coordinate development teams integrating engagement platforms with upstream and downstream systems, including CRM, web, and analytics platforms.
  • Ensure solutions meet compliance, auditability, and regulatory requirements for external engagement and healthcare interaction workflows.
  • Apply and reinforce standard engagement workflows across brands, markets, and channels.
  • Enable automation and optimization of engagement processes to improve efficiency and user experience.
  • Partner with business, IT security, and vendor teams to ensure technical solutions adhere to organizational standards, security policies, and regulatory requirements.
  • Organize and direct vendor partners' technical work to align with capability priorities, delivery timelines, and enterprise standards.
  • Partner with the Customer Operations Technical Suite Lead to escalate and resolve complex technical challenges spanning Global Capability teams.
  • Mentor and guide software engineers and developers to elevate the team's technical capability.
  • Lead cross-team problem solving and resolution of technical challenges within the Global Capability team.
Desired Qualifications
  • Proven experience building full-stack applications for external-facing customer or consumer applications and partnering closely with business teams.
  • Experience in pharmaceutical or healthcare industries.
  • Experience partnering with enterprise platform teams or product teams supporting digital and operational capabilities.
  • Experience in rare disease or specialty brands, with an understanding of their stakeholder dynamics.

About the company

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $1.21 billion; Jazz raised full-year guidance to $4.68 billion.
  • Actio's ABS-1230 adds first-in-class KCNT1 epilepsy upside after the September 15, 2026 close.
  • Oncology revenue exceeded $1 billion in 2025, driven by Zepzelca and Ziihera.

What critics are saying

  • Xywav faces Lupin, Teva, and Tris patent fights; generic entry threatens 2027 cash flow.
  • Xywav and EPIDIOLEX still dominate value; one patent loss or safety issue would crush earnings.
  • Jazz paid $820 million for Actio before registrational proof; ABS-1230 can still fail.

What makes Jazz Pharmaceuticals unique

  • Ziihera launched August 2026, targeting $3B-$5B across HER2-positive tumors.
  • EPIDIOLEX holds exclusivity into the late 2030s and now funds four new trials.
  • Xywav's low-sodium oxybate formulation keeps narcolepsy patients despite generic Xyrem pressure.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Oct 16th, 2026
Jazz wins FDA approval for Ziihera as commercial chief Pearce plans to retire; 2026 guidance $4.6B+

Jazz Pharmaceuticals has won US Food and Drug Administration (FDA) approval for its cancer drug Ziihera. The approval raised the drug's projected peak sales range. Separately, chief commercial officer Samantha Pearce plans to retire by June 30, 2027, or when a successor is appointed. Jazz has started an internal and external search. In its second-quarter 2026 update, Jazz reported revenue of $1,208.3 million and raised full-year 2026 guidance to $4.60–4.75 billion. The share price still fell 7.6% after earnings. Simply Wall St's narrative projects revenue of $5.7 billion and earnings of $1.7 billion by 2029, implying a fair value of $294.27 a share.

Yahoo Finance
Sep 20th, 2026
Jazz Pharma raises zanidatamab peak sales target to $3B-$5B as oncology revenue hits $1B

Jazz Pharmaceuticals reported its oncology revenue surpassed $1 billion in 2025, marking a 32% year-over-year increase. The growth follows three recent product launches, including zanidatamab, Modeyso and Zepzelca's FORTE regimen. The company raised zanidatamab's estimated peak-sales opportunity to $3 billion-$5 billion. Jazz aims to increase HER2-directed treatment adoption in gastroesophageal cancer, where only 60% of eligible HER2-positive patients currently receive such therapy. Jazz estimates the US incidence of HER2-positive gastroesophageal adenocarcinoma at approximately 8,000 patients, with a labelled population of 3,000 to 4,000 patients. The company is also developing zanidatamab for biliary tract cancer, colorectal cancer, non-small cell lung cancer and breast cancer. Jazz maintains commercial investment whilst preserving financial flexibility for acquisitions across oncology, epilepsy and sleep disorders.

Yahoo Finance
Sep 11th, 2026
Jazz Pharmaceuticals stock climbs 29.7% but analysts warn of declining margins and weak returns

Jazz Pharmaceuticals' stock has risen 29.7% over the past six months, outpacing the S&P 500 by 17 percentage points to reach $240.49 per share. However, analysts point to concerning trends in the company's fundamentals. The company's adjusted operating margin has declined by 2.6 percentage points over five years, despite revenue growth that should have improved economies of scale. Its trailing 12-month adjusted operating margin stood at 41.7%. Additionally, Jazz Pharmaceuticals' five-year average return on invested capital was just 2.7%, below the typical cost of capital for healthcare companies. This suggests mediocre efficiency in deploying capital for growth. The stock currently trades at 9.6× forward price-to-earnings ratio. Analysts consider this valuation reasonable but believe the company's weakening fundamentals present downside risk.

StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.